Skip to main content
Top
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Metastasis | Case Study

Is it time for redefining oligometastatic disease? Analysis of lung metastases CT in ten tumor types

Authors: Ofer N. Gofrit, Ben Gofrit, Yuval Roditi, Aron Popovtzer, Steve Frank, Jacob Sosna, S. Nahum Goldberg

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

Background

Oligometastatic disease (OD) is usually defined arbitrarily as a condition in which there are ≤ 5 metastases. Given limited disease, it is expected that patients with OD should have better prognosis compared to other metastatic patients and that they can potentially benefit from metastasis-directed therapy (MDT). In this study, we attempted to redefine OD based upon objective evidence that fulfill these assumptions.

Methods

Chest CTSs of 773 patients with 15,947 lung metastases originating from ten malignancy types were evaluated. The number and largest diameter of each metastasis was recorded. Metastatic cluster was defined as a cluster of two or more metastases with diameter difference ≤ 1 mm. The prognostic power of seven statistical models on overall survival (OS) was analyzed.

Findings

Both the number of metastases and metastatic clusters had a highly significant impact on OS (p < 0.0001, p = 0.003 respectively). Patients with a single metastasis or a single cluster of metastases (regardless of metastases number), equaling 16.2% of all patients, had significantly better prognosis compared to other patients (p = 0.0002). If metastases diameter variability is ignored, as in the standard definition of OD, then patients with 2–5 and 6–10 metastases would have a similar prognosis.

Interpretation

Patients with a single cluster of metastases, theoretically originating from a single clone, have significantly better prognosis compared to patients with more than one cluster. Using this definition can potentially improve the results of MDT. The upper limit of metastases number should be determined by the technical capabilities of the MDT used.
Appendix
Available only for authorised users
Literature
4.
go back to reference Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020;38(25):2830–8. https://doi.org/10.1200/JCO.20.00818. (Epub 2020 Jun 2. PMID: 32484754; PMCID: PMC7460150).CrossRef Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020;38(25):2830–8. https://​doi.​org/​10.​1200/​JCO.​20.​00818. (Epub 2020 Jun 2. PMID: 32484754; PMCID: PMC7460150).CrossRef
7.
go back to reference Yamamoto T, Niibe Y, Matsumoto Y, Onishi H, Aoki M, Nishikawa A, et al. Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma. J Radiat Res. 2020;61(6):935–44. https://doi.org/10.1093/jrr/rraa071. (PMID:32940330;PMCID:PMC7674693).CrossRef Yamamoto T, Niibe Y, Matsumoto Y, Onishi H, Aoki M, Nishikawa A, et al. Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma. J Radiat Res. 2020;61(6):935–44. https://​doi.​org/​10.​1093/​jrr/​rraa071. (PMID:32940330;PMCID:PMC7674693).CrossRef
9.
go back to reference Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28. https://doi.org/10.1016/S1470-2045(19)30718-1. (PMID: 31908301).CrossRef Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28. https://​doi.​org/​10.​1016/​S1470-2045(19)30718-1. (PMID: 31908301).CrossRef
10.
go back to reference Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–53. https://doi.org/10.1200/JCO.2017.75.4853. (Epub 2017 Dec 14 PMID: 29240541).CrossRef Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–53. https://​doi.​org/​10.​1200/​JCO.​2017.​75.​4853. (Epub 2017 Dec 14 PMID: 29240541).CrossRef
Metadata
Title
Is it time for redefining oligometastatic disease? Analysis of lung metastases CT in ten tumor types
Authors
Ofer N. Gofrit
Ben Gofrit
Yuval Roditi
Aron Popovtzer
Steve Frank
Jacob Sosna
S. Nahum Goldberg
Publication date
01-12-2023
Publisher
Springer US
Keyword
Metastasis
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00625-2

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine